On September 17, 2019, Sienna Biopharmaceuticals, Inc., filed a petition for relief under Chapter 11 of the Bankruptcy Code in the Bankruptcy Court for the District of Delaware (Lead Case No. 19-12051-CSS). Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The Debtor reports assets and liabilities both in the range of $50,000,001-100 million (total assets of $107,625,000.00 and debts of $80,642,000.00), estimated creditors of between 200-999, and funds are presently expected to be available for distribution to unsecured creditors.
Cole Schotz does not represent the Debtors in this case. We are posting this for informational purposes only. If you have received a notice and have any questions, you should contact Debtors’ counsel.